- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Oncology
- Nephrology
- Neurology
- Pulmonology
Bimekizumab Demonstrates Sustained Efficacy in Moderate-to-Severe Plaque Psoriasis Over Five Years
AAD 2025. New research indicates that dual inhibition of IL-17A and IL-17F with bimekizumab maintains high rates of complete skin clearance for up to 5 years.
Long-term data from the phase 3 BE BRIGHT extension clinical trial presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting highlight the sustained efficacy of bimekizumab-bkzx (BIMZELX®) in adults with moderate-to-severe plaque psoriasis (PSO). The findings, released by UCB, indicate that dual inhibition of interleukin (IL)-17A and IL-17F with bimekizumab maintains high rates of complete skin clearance for up to 5 years.
Among a subgroup of 153 patients from the US and Canada who completed 5 years of treatment, 67.7% achieved complete skin clearance as measured by the Psoriasis Area and Severity Index (PASI100). Additionally, 84.9% of patients achieved near-complete skin clearance (PASI90). The treatment was generally well tolerated, with no unexpected safety findings reported.
Bimekizumab demonstrated durable and broad efficacy across multiple patient subgroups over 4 years, including those with cardiometabolic comorbidities and varying body weights:
- Among 420 patients weighing <90 kg at baseline, 67.4% achieved PASI100 at 4 years.
- Among 351 patients weighing ≥90 kg at baseline, 61.6% achieved PASI100 at 4 years.
- Among patients with hypertension, hyperglycemia, or elevated BMI, PASI100 response rates ranged from 56.9% to 60.7% at 4 years.
In patients with PSO who were at risk of developing psoriatic arthritis (PsA), 68.7–71.6% achieved PASI100 at 3 years. These outcomes were consistent with the overall bimekizumab-treated group.
The most common treatment-emergent adverse events over five years included nasopharyngitis (9.7 events per 100 patient-years), oral candidiasis (7.6 events per 100 patient-years), and upper respiratory tract infections (5.8 events per 100 patient-years).
"A primary treatment goal for people living with psoriasis is durable, high rates of complete skin clearance. These five-year bimekizumab-bkzx results provide valuable evidence for clinical decision-making,” Andrew Blauvelt, MD, MBA, Chair of the Medical Board at the National Psoriasis Foundation, said in a press release. "The sustained complete skin clearance offers important insights into the potential of bimekizumab-bkzx's dual inhibition to provide long-term management of this chronic inflammatory condition."
Reference: BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis. News item. UCB. March 7, 2025. Accessed March 7, 2025. https://www.prnewswire.com/news-releases/bimzelx-bimekizumab-bkzx-five-year-data-at-aad-2025-showed-sustained-skin-clearance-and-long-term-efficacy-in-moderate-to-severe-plaque-psoriasis-302395620.html
Ruxolitinib Cream 1.5% Demonstrates Efficacy in Prurigo Nodularis: Phase 3 Findings
March 8th 2025Data from the TRuE-PN trial program were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, offering important insights into potential new therapeutic options for this debilitating condition.
